High-dose, conventionally fractionated thoracic reirradiation for lung tumors

Griffioen, Gwendolyn H.M.J.; Dahele, Max; Haan, Patricia F. de; Ven, Peter M. van de; Slotman, Ben J.; Senan, Suresh

doi:10.1016/j.lungcan.2013.12.006

Cited by 37 publications

(34 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our experience with high-dose thoracic re-irradiation for new or recurrent lung cancer in a previously irradiated region has been published in Lung Cancer [1]. As was apparent from a recent literature review [2], our report appears to be one of the largest available on conventional re-irradiation and also has one of the longest follow up periods.…”

Section: Dear Editormentioning

confidence: 73%

See 1 more Smart Citation

High-dose conventional thoracic re-irradiation for lung cancer: Updated results

et al. 2015

Self Cite

View full text Add to dashboard Cite

Section: Dear Editormentioning

confidence: 73%

“…Of these, three patients had been described in our initial publication [1], all of whom had massive bleeding. In addition, two other patients died of respiratory failure (after about 6 and 20 months), both of whom had also developed lung cavitation.…”

Section: Dear Editormentioning

confidence: 99%

High-dose conventional thoracic re-irradiation for lung cancer: Updated results

et al. 2015

Self Cite

View full text Add to dashboard Cite

“…Considering the institutional feasibility, tumor recurrence patterns, and patient characteristics, re-irradiation with traditional photon therapy is more common in daily practice; however, reports of the results of this treatment are scarce. Although several retrospective studies with small cohorts have reported the clinical outcomes of photon thoracic re-irradiation [23][24][25], the optimal RT dose, toxicities, and clinical outcomes remain unclear.…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer

Yang

Hsu

Chen

et al. 2020

Clinical and Translational Radiation Oncology

View full text Add to dashboard Cite

Background and purpose: Thoracic re-irradiation may be an alternative treatment for lung cancer patients who develop intrathoracic locoregional recurrence without systemic progression. This study aimed to retrospectively assess locoregional control, clinical outcomes, and toxicities in lung cancer patients who received thoracic re-irradiation. Materials and methods: We retrospectively reviewed 50 lung cancer patients who received thoracic reirradiation using conventional photon radiotherapy (RT) and stereotactic body radiotherapy (SBRT) between 2009 and 2017. The correlations of clinicopathologic factors, treatment factors, and dosimetric factors of RT with time to local progression (TTLP), progression-free survival (PFS), and overall survival (OS) after starting thoracic re-irradiation were calculated using log-rank tests and Cox regression models. Results: The median re-irradiation dose in equivalent dose in 2-Gy fractions was 51.1 Gy, and the mean re-irradiation planning target volume was 201.58 ml. The median mean lung dose (MLD) was 4.18 Gy, and the total lung volumes receiving a dose of 5 Gy (lung V5) and of 20 Gy (V20) were 19.8% and 5.85%, respectively. The TTLP, PFS, and OS were 18.0, 5.9, and 25.1 months, respectively. Lung V5 (p < 0.001), V20 (p = 0.011), and MLD (p = 0.002) were significantly associated with grade 2 lung toxicity. Seven (14%) patients developed lethal lung events. Subsequent chemotherapy following thoracic reirradiation was significantly correlated with lethal lung events (p = 0.009). Conclusion: Promising local control can be achieved with thoracic re-irradiation in lung cancer patients with locoregional recurrence. However, unexpected lethal lung events may occur, especially in patients receiving systemic therapy following thoracic re-irradiation.

show abstract

“…Griffioen et al reported a retrospective review of 24 patients treated with high-dose re-irradiation [14], including 11 patients being treated for a new primary cancer. The majority of patients were stage III at recurrence and initial treatment.…”

Section: Ebrt After Ebrtmentioning

confidence: 99%

Re-irradiation in lung cancer

2015

View full text Add to dashboard Cite

Local-regional control is an important component of care for patients treated for lung cancer. Local-regional disease progression can lead directly to problems including pain, dysphagia, hemoptysis, cough, dyspnea, superior vena cava syndrome, and death. Local-regional failure remains common despite advances in radiation therapy, chemotherapy, and surgery. For patients and caregivers, local-regional failure management poses a dilemma for balancing safety and efficacy. Multiple strategies for local-regional failure management exist. This report examines data from the use of external beam radiation therapy, stereotactic body radiotherapy, and endobronchial brachytherapy for management of localregional failure in lung cancer.

show abstract

High-dose, conventionally fractionated thoracic reirradiation for lung tumors

Cited by 37 publications

References 28 publications

High-dose conventional thoracic re-irradiation for lung cancer: Updated results

High-dose conventional thoracic re-irradiation for lung cancer: Updated results

Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer

Re-irradiation in lung cancer

Contact Info

Product

Resources

About